Results 41 to 50 of about 35,617 (253)
FEBS Letters, EarlyView.Animals must match their growth rate to available nutrients. We show that in Drosophila larvae, the nutrient‐sensing TOR kinase controls growth by regulating levels of TFAM, a key regulator of mitochondrial function, in the adipose tissue. When nutrients are abundant, high TOR activity suppresses TFAM, lowering mitochondrial bioenergetic activity and ...
Shrivani Sriskanthadevan‐Pirahas +4 more
wiley +1 more source
Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance
ESC Heart Failure, 2022 Aims Heart failure (HF) is the most frequent cause of hospital admission among patients 65 years or older. Patients hospitalized for acutely decompensated chronic HF and ‘de novo’ acute heart failure (AHF) continue to experience unacceptably high post ...
João Pedro Ferreira +4 more
doaj +1 more source
A case report of euglycemic ketoacidosis due to dapagliflozin treatment
Turkish Journal of Internal Medicine, 2021 Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
Murat Çalapkulu +4 more
doaj +1 more source
Sodium-glucose co-transporter 2 inhibitors and erythrocytosis: a review
British Journal of Diabetes, 2022 Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a class of anti-hyperglycaemic agents widely used in the treatment of type 2 diabetes mellitus (T2DM). They function by reducing renal glucose reabsorption and thereby promote urinary glucose excretion, resulting in improvement in glycaemic control. In large-scale clinical trials, SGLT2i have been
Najeeb Shah +5 more
openaire +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
ESC Heart Failure, 2022 Aims Recent trials have evaluated sodium–glucose co‐transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI).
Muhammad Shariq Usman +9 more
doaj +1 more source
Cardiology Journal, 2023 Several mechanisms have been suggested to explain positive cardiovascular effects observed in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Jacek Kubica +24 more
doaj +1 more source
Molecular Oncology, EarlyView.Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant +11 more
wiley +1 more source
JACC: Basic to Translational Science, 2019 Summary: Recent studies send an unambiguous signal that the class of agents known as sodium-glucose–linked co-transporter-2 inhibitors (SGLT2i) prevent heart failure hospitalization in patients with type 2 diabetes. However, the mechanisms remain unclear.
Kim A. Connelly, MBBS, PhD +7 more
doaj +1 more source
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Frontiers in Cardiovascular Medicine, 2022 A new therapeutic class of oral agents firstly used for the treatment of type 2 diabetes mellitus is represented by gliflozines or sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Annamaria Mascolo +17 more
doaj +1 more source